Victor J. Nickolson

BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands.

BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands.